DV
Dividend Vision

SHPH — Shuttle Pharmaceuticals Inc

Shuttle Pharmaceuticals Inc (SHPH)

Total return is -100.0% over the past 4 years, 207.2 points behind SPY at 107.2%. Its deepest 1-year drawdown was 94.2%.

Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company that develops novel cancer therapies using an AI-driven platform for molecular discovery and early-stage drug development. The company does not currently distribute dividends or other income to shareholders. Shuttle Pharmaceuticals appeals primarily to investors seeking exposure to early-stage biotech development rather than those focused on current income generation.

SHPH key facts

Asset type
Stock
Asset class
Equity
Inception date
08/31/2022
Last close
$4.07
Market cap
$1,772,940
Average volume
44357.0
Beta
1.289
Payout ratio
0.0
P/E ratio
30.3
Forward P/E
0.0
EPS
$0.10